PFE · News · 20260922N

Drug Pricing Policy

PFIZER INC · 2026-09-22 · Importance 47 · Surprise 60

Analyst reporting identified the rollout of most-favored-nation Medicaid pricing as a factor clouding Pfizer's near-term outlook. The policy could affect U.S. Medicaid pricing and revenue for products subject to the rollout, although the digest does not quantify the expected dollar impact. The issue is presented alongside Vyndaqel softness and reduced COVID-19 product expectations.